Načítá se...
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of patients who have an observed tumour shrinkage above a predefined level...
Uloženo v:
| Vydáno v: | Stat Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5724692/ https://ncbi.nlm.nih.gov/pubmed/28850689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.7453 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|